SARS-CoV-2 S protein RBD containing C-terminal His Tag. The protein was expressed in human 293 cells (HEK293). It contains amino acids Arg 319 - Lys 537.
SARS-CoV-2 (COVID-19) Spike Neutralization Antibody is supplied in PBS.
Form:
Liquid
Application Dilute:
Optimal dilutions for each application to be determined by the researcher.
Figure 3 ELISA Validation with RBDs of SARS-CoV-2 Variants Antibodies: SARS-CoV-2 (COVID-19) Spike RBD Antibody, SD9855. A direct ELISA was performed using RBD protein of SARS-CoV-2 variants (wild-type, alpha, beta, gamma and Delta) as coating antigens at 1 &956,g/mL and the anti-SARS-CoV-2 (COVID-19) RBD antibody (SD9853) as the capture antibody, followed by anti-cMyc-tag antibody (PM-7669) at 1 &956,g/mL. Secondary: Goat anti-mouse IgG HRP conjugate at 1:5000 dilution. SD9853 binds to RBDs of all the variants tested.
Figure 2 ACE2-RBD binding inhibitory ELISAAntibodies: SARS-CoV-2 (COVID-19) Spike RBD Antibodies, SD9855. ACE2-RBD binding inhibitory ELISA was performed using RBD protein of SARS-CoV-2 variants (wild-type, alpha, beta, epsilon, gamma and kappa) as coating antigens at 1 &956,g/mL and the anti-SARS-CoV-2 (COVID-19) RBD antibody SD9855 as the capture antibody, followed by incubation with 20 ng/mL human ACE2-Fc. Bound h-ACE2-Fc was detected with a goat anti-human IgG-HRP conjugate (1:20,000 dilution) using the TMB chromogenic substrate system. SD9855 exhibited a dose dependent inhibitory effect on ACE2 binding to RBDs of all the variants tested.
Figure 6 ACE2-RBD binding inhibitory ELISAAntibodies: SARS-CoV-2 (COVID-19) Spike RBD Antibodies, SD9853 (A10) and SD9855 (E10). ACE2-RBD binding inhibitory ELISA was performed using RBD protein of SARS-CoV-2 variants (wild-type and alpha) as coating antigens at 1 &956,g/mL and the anti-SARS-CoV-2 (COVID-19) RBD antibody (SD9853 and SD9855) as the capture antibody, followed by incubation with 20 ng/mL human ACE2-Fc. Bound h-ACE2-Fc was detected with a goat anti-human IgG-HRP conjugate (1:20,000
Figure 1 Pseudovirus neutralization assayAntibodies: SARS-CoV-2 (COVID-19) Spike RBD Antibodies, SD9855 (E10). Luciferase reporter virus-like particles and 293T-hsACE2 cells were used for the assay. After 72 hrs incubation infectivity was measured by luciferase expression using Promega Renilla-Glo Luciferase Assay System. Infectivity was measured as RLUs and no sdAb control was set to 100% infectivity. Neutralization activity of SD9855 (E10) was measured over a serial dilution to determine the half-maximal inhibitory concentration (IC50). SD9855 (E10) exhibited a dose dependent neutralizing effect on all the variant pseudoviruses tested.
Figure 4 Pseudovirus neutralization assayAntibodies: SARS-CoV-2 (COVID-19) Spike RBD Antibodies, SD9853 (A10) and SD9855 (E10). Luciferase reporter virus-like particles and 293T-hsACE2 cells were used for the assay. After 72 hrs incubation infectivity was measured by luciferase expression using Promega Renilla-Glo Luciferase Assay System. Infectivity was measured as RLUs and no sdAb control was set to 100% infectivity. Neutralization activity of SD9853 (A10) and SD9855 (E10) was measured over a serial dilution series to determine the half-maximal inhibitory concentration (IC50). Both SD9853 (A10) and SD9855 (E10) exhibited a dose dependent neutralizing effect on wild-type pseudoviruses, and the combination of the two showed a significantly synergistic effect.
Figure 5 Pseudovirus neutralization assayAntibodies: SARS-CoV-2 (COVID-19) Spike RBD Antibodies, SD9853 (A10) and SD9855 (E10). Luciferase reporter virus-like particles and 293T-hsACE2 cells were used for the assay. After 72 hrs incubation infectivity was measured by luciferase expression using Promega Renilla-Glo Luciferase Assay System. Infectivity was measured as RLUs and no sdAb control was set to 100% infectivity. Neutralization activity of SD9853 (A10) and SD9855 (E10) was measured over a serial dilution series to determine the half-maximal inhibitory concentration (IC50). Both SD9853 (A10) and SD9855 (E10) exhibited a dose dependent neutralizing effect on alpha pseudoviruses, and the combination of the two showed a significantly synergistic effect.
* VAT and and shipping costs not included. Errors and price changes excepted
